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In the airways, adenine nucleotides support a complex sig-
naling network mediating host defenses. Released by the epi-
thelium into the airway surface liquid (ASL) layer, they regu-
late mucus clearance through P2 (ATP) receptors, and
following surface metabolism through P1 (adenosine; Ado)
receptors. The complexity of ASL nucleotide regulation pro-
vides an ideal subject for biochemical network modeling. A
mathematical model was developed to integrate nucleotide
release, the ectoenzymes supporting the dephosphorylation
of ATP into Ado, Ado deamination into inosine (Ino), and
nucleoside uptake. The model also includes ecto-adenylate
kinase activity and feed-forward inhibition of Ado produc-
tion by ATP and ADP. The parameters were optimized by
fitting the model to experimental data for the steady-state
and transient concentration profiles generated by adding
ATP to polarized primary cultures of human bronchial epi-
thelial (HBE) cells. The model captures major aspects of ATP
and Ado regulation, including their >4-fold increase in con-
centration induced by mechanical stress mimicking normal
breathing. The model also confirmed the independence of
steady-state nucleotide concentrations on the ASL volume,
an important regulator of airway clearance. An interactive
approach between simulations and assays revealed that feed-
forward inhibition is mediated by selective inhibition of ecto-
5-nucleotidase. Importantly, the model identifies ecto-ad-
enylate kinase as a key regulator of ASL ATP and proposes
novel strategies for the treatment of airway diseases charac-
terized by impaired nucleotide-mediated clearance. These
new insights into the biochemical processes supporting ASL
nucleotide regulation illustrate the potential of this mathe-
matical model for fundamental and clinical research.
Mucociliary clearance (MCC)4 constitutes the first line of
defense against airway infection (1). Inhaled pathogens are
trapped by a mucus layer, positioned above ciliated epithelia
by a periciliary (PCL) layer. Together, mucus and PCL form
the ASL layer, which is continuously transported cephalad
by coordinated ciliary beating. Through their interactions
with P2 receptors, adenine nucleotides regulate all major
epithelial functions supporting MCC, including Cl/liquid
secretion via the Ca2-activated Cl channel and the cystic
fibrosis transmembrane regulator (CFTR) (2), mucin secre-
tion (3, 4), and ciliary beat activity (5, 6). Nucleotides are
released by the epithelium into the ASL layer under basal
conditions (7, 8), and their release rate increases in response
to mechanical stress imparted by tidal breathing (8–12).
Nucleotide-mediated epithelial responses are modified by
surface enzymes (ectonucleotidases) that convert a fraction
of the ATP into Ado (13–15). This nucleoside activates air-
way epithelial signaling pathways through P1 receptors, typ-
ically the A2B receptor, which stimulates ciliary beat activity
(16) and Cl/liquid secretion by CFTR (17). In healthy air-
ways, the purinergic regulation of MCC is mediated by both
P1 and P2 receptor-mediated responses (10, 18). In chronic
lung diseases, the accelerated metabolism of ATP (14) can
lead to severe complications related to airway obstruction
and inflammation (2, 19). The cystic fibrosis (CF) patients
are particularly vulnerable to infection because of the sole
dependence of MCC on P2 receptor-mediated signaling,
reflecting the absence of the final effector for P1 signaling,
i.e. functional CFTR. This information led to the current
interest in aerosolized nucleotide analogs for the improve-
ment of MCC (19).
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Despite the importance of purinergic signaling for airway
defenses, it has not been possible, until recently, to develop a
mathematical model of ASL nucleotide regulation because of
the absence of quantitative information regarding ASL nucleo-
tide and Ado levels, the rates of nucleotide release and Ado
uptake, and the kinetic properties of the ectonucleotidases. In
the past decade, extensive work has been conducted to charac-
terize ATP release from the apical surface of HBE cells (7, 8,
10–12, 20, 21). Members of the three ecto-ATPase families
(alkaline phosphatases, ecto-nucleoside triphosphate diphos-
phohydrolases (E-NTPDases), and nucleotide pyrophos-
phatase/phosphodiesterases (E-NPPs)) (22, 23) have been
identified on HBE cells (13–15, 24–26), along with ecto-AK
(2ADP7ATP  AMP) (27, 28). Also, Ado levels are regulated
on HBEs by a balance between the production rate (AMP 3
Ado) by ecto-5-NT andNSAP (13) and the elimination rate by
Ado deaminase 1 (ADA1; Ado 3 Ino) and cellular uptake by
concentrative nucleoside transporter 3 (CNT3) (29).
Based on these findings, we developed amathematicalmodel
of ASL nucleotide regulation. The kinetic coefficients were
optimized by fitting the output of the model to experimental
values of ASL nucleotide and Ado concentrations, nucleotide
release rates (12, 20), ATP metabolism (13, 26, 28), and Ado
uptake (29). The capacity of themodel to reproduce the impact
of physical parameters (ASL volume andmechanical stress) and
functional interactions between network components was ver-
ified by biochemical assays on primary cultures of HBE cells.
This study provides the first mathematical approach to the
investigation of an important defense mechanism in human
airways.
EXPERIMENTAL PROCEDURES
Cell Culture—Model validation was conducted on HBE cul-
tures maintained at air-liquid interface, as described previously
(30). The epithelial cells were obtained from healthy donors at
the time of transplantation by the Tissue Culture Core of the
Cystic Fibrosis Center (University ofNorthCarolina) under the
auspices of protocols approved by the Institutional Board of
Review. They were isolated by protease digestion, seeded on
12-mm permeable supports (0.45 m pores, T-Clear; Costar)
coated with human type IV collagen, and kept in Ham’s F-12-
basedmedium supplementedwith 5gml1 transferrin, 30 nM
triiodothyronine, 1 M hydrocortisone, and 3.75 gml1
endothelial cell growth substance. The confluent cultures
were maintained at air-liquid interface with medium on the
basolateral side. After 4 weeks, they were composed of cili-
ated and secretory cells, with transepithelial electrical resist-
ance 300 ohms/cm2.
Cyclic Compressive Stress (CCS)—The HBE cultures were
subjected to 1 h of CCS mimicking normal tidal breathing
(20 cm of H2O; 20 cycles/min) using a system enclosed in an
incubator (37 °C; 5% CO2) (10). Two pieces of tubing, each
containing a high speed solenoid valve, were inserted into a
conical silicon plug fitted to the top of the T-Clear, one con-
nected to a pressurized chamber and the other connected to
the incubator atmosphere. A microprocessor regulated the
amplitude and frequency of the chamber pressure applied to
the culture by controlling the open/closed state of the sole-
noid valves (10).
Biochemical Measurements of Steady-state Nucleotide
Concentrations—The steady-state ASLATP concentrationwas
measured on HBE cultures by luminometry using soluble lucif-
erase or a chimeric Staphylococcus aureus protein A-luciferase
attached to the apical surface via keratan sulfate-specific anti-
bodies (20). Steady-state concentrations of ATP, ADP, AMP,
and Ado were determined on HBE cultures by ethenyl derivat-
ization and fluorescence high pressure liquid chromatography
(HPLC) (12).
Transient Nucleotide Concentration Profiles and Ectonucle-
otidase Activities—HBE cultures were preincubated 30 min
(37 °C; 5% CO2) in Krebs buffer (pH 7.5) (0.35 ml; bilateral).
Then 0.1–1000 M ATP was added to the apical surface to
determine the transient concentration profile and initial rate of
ATP hydrolysis by HPLC analysis of buffer samples collected
over 60 min (14). The contribution of each ectoenzyme was
calculated from paired assays conducted on the same culture
wells before and after pretreatment with selective noncom-
petitive inhibitor(s). The kinetic parameters of NSAP for
ATP and ADP were determined as described previously for
AMP (13), but in the presence of 0.5 mM Ap5A to inhibit
ecto-AK (ATP  AMP 7 2ADP) (28). NSAP activity was
calculated from the difference in linear rate of substrate
hydrolysis measured before and after exposure to 10 mM
levamisole, at each substrate concentration (0.1–1000 M).
Michaelis constants (KM) and maximal velocities (Vmax)
were calculated as shown previously (13).
Kinetic Model of Airway ATP/Ado Regulation—This section
outlines the theory and methodology used to build the mathe-
matical model of airway nucleotide regulation on the apical
surface of human airway epithelia. A biochemical network was
derived using quantitative data gathered from the literature on
nucleotide release (12, 20) and metabolism (13–15, 24, 26) by
HBE cultures (Fig. 1). Because UTP levels are about 15% that of
ATP (25) in the ASL layer, the influence of uridine nucleotides
on ATP regulation was considered negligible. Therefore, the
reactions governing ATP dephosphorylation to Ado and Ado
deamination are as shown in Reactions 1–5,
ATP3 ADP  Pi
REACTION 1
ADP3 AMP  Pi
REACTION 2




ATP3 AMP  PPi
REACTION 5
Each of the above reactions was assumed to follow Michaelis-
Menten kinetics of the form shown in Equation 1,
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 j  S
(Eq. 1)
where [S] is the substrate concentration, and Vmax(j) and KM(j) are
themaximum velocity andMichaelis constant. The superscript
j is used to index themultiple enzymes involved in the pathway.
In contrast, the reversible ecto-AK Reaction 6,
ATP  AMP7 2ADP
REACTION 6
which involves two binding sites, has been shown to follow a Bi



























This expression is a generalization of Michaelis-Menten kinet-
ics that relies on the same underlying assumptions. The model
also incorporates the feed-forward inhibition of AMP hydroly-
sis byATP andADP. Experimental evidence indicates that ATP
and ADP competitively bind to enzymes that catalyze AMP






 j1  ATPKATPin  ADPKADPin   AMP
(Eq. 3)
Although it is possible that the inhibition constantsKATPin and
KADPin may differ for ecto-5-NT and NSAP, these values were
assumed identical for simplicity. The remaining elements that
were incorporated into the model are the rates of ATP release
and Ado/Ino uptake. In accordance with experimental obser-
vations (12), the basal rate of ATP release (JATP) was considered
constant. Because Ado and Ino are taken back into the cell
through CNT3, and therefore compete for access to the trans-
porter, this effect is modeled using the following rates for Ado





















which allows for the possibility of different Vmax and KM values
for the two molecules.
One of the functions of nucleotide release is to stimulate
liquid secretion, which in turn may affect ASL nucleotide con-
centrations. Under static conditions, the basal rate of release
does not maintain ATP at sufficiently high levels to activate P2
receptors (12). However, Ado levels generated from ATP
metabolism under static conditions stimulate liquid secretion
into the ASL layer via the A2B receptor-CFTR pathway (17).
Therefore, the model equations were derived for the general
condition of a time-dependent ASL volume. To illustrate how
the ASL volume enters the model, consider a simple case in
which ATP is released into the ASL at a constant rate of JATP
molecules/s, and then hydrolyzed by enzyme E. The surface
area is denoted by A, and [E]T represents the surface density of
E, expressed inmolcm2. IfV indicates ASL volume, the equa-

















where (kcatA)/(V)[E]T corresponds tomaximumvelocity (Vmax)
and the last term models changes in ATP concentration
because of the changing ASL volume. The considerations dis-
cussed above led to the formulation of five equations to
describe the regulation of adenine nucleotides in the ASL layer
(Equations 7–11). All model simulations were performed in
MatLab (Mathworks, Natick, MA) using the ordinary differen-
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Linear Model for the Steady-state Nucleotide Concentrations—
The biochemical data showed that, under physiological condi-
tions, steady-state nucleotide concentrations are orders of
magnitude lower than theKM values of the enzymatic reactions
(12). Hence, to a good approximation, the Michaelis-Menten













 j S  Pk  S (Eq. 12)
where the parameter P(k) denotes the sum of the ratios of Vmax(j)
toKM(j) for all enzymes catalyzing the same reaction. The expres-
sions for Ado and Ino uptake can be simplified in a similar way.
The reversible ecto-AK reaction (Reaction 6) is a second order
reaction requiring two substrates and therefore does not con-
tribute significantly to the regulation of ASL nucleotide con-
centrations under steady-state conditions. Also, steady-state
ATP andADP levels are 1000-fold lower than theirKi values for
the feed-forward inhibition reaction (13) and therefore insuffi-
cient to inhibit AMP. Therefore, these equationswere excluded
from the linear model. Using these simplifications, Equations
7–11 can be approximated under steady-state conditions by the
following set of linear Equations 13–17,
JATP  P
1  P5ATPss  0 (Eq. 13)
P1ATPss  P
2ADPss  0 (Eq. 14)
P5ATPss  P
2ADPss  P
3AMPss  0 (Eq. 15)
P3AMPss  P
4Adoss  U
1Ado  0 (Eq. 16)
P4Adoss  U
2Inoss  0 (Eq. 17)
where U(1) and U(2) result from linearizing the expressions for
Ado (Equation 4) and Ino (Equation 5) uptake, respectively.
Statistical Analysis—All biochemical assays were conducted
onHBE cultures from5 subjects (	S.E.), and themean exper-
imental value was considered nonsignificantly different from
the corresponding simulated value when 
15% different.
RESULTS
Generation of the Experimental Data Set for Model Parame-
terOptimization—The strength of thismodel resides in the fact
that all biochemical data were acquired from a single experi-
mental system, polarized primary cultures of HBE cells main-
tained under air-liquid interface conditions and assayed in a
physiological buffered solution (pH 7.5). Such consistency
allowed us to combine data gathered over a decade into one
experimental data set (Table 1, column A).
The first kinetic parameters of ATP and ADP hydrolysis
measured on HBE cultures represent the sum of all apical ecto-
ATPase and ecto-ADPase activities (26). More recently, we
determined the kinetic properties of ecto-AK (Vmax(f) , KATP(f) ,
KAMP(f) , Vmax(b) , and KADP(b) ; Table 1, column A) (28) and E-NPPs
(Vmax(10) andKM(10); Table 1, columnA) (24) on these cells. Based on
this information, the kinetic measurements of ATP and ADP
hydrolysis were repeated in the presence of the ecto-AK inhib-
itor, Ap5A (28), to eliminate the influence of the nonlinear reac-
tion (ATPAMP7 2ADP). Under these conditions, the ecto-
ATPase and ecto-ADPase activities described by Vmax(1–5) (Table
1, column A) combined the activities of two enzyme families:
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showed thatHBE cells expressNTPDase 1 andNTPDase 3 (15).
It is important to note that theKM corresponds to the substrate
affinity of an enzyme, which is independent of cell type or
expression level, whereasVmax constitutes a quantitativemeas-
ure of the expression level of an enzyme (33). Because specific
inhibitors of NTPDase 1 are currently unavailable, NTPDase 1
and NTPDase 3 were assigned to the parameter sets with KM
values approximating (	10%) their KM (Table 1, column A), as
reported for purified humanNTPDase 1 (ATP, 10 M; ADP, 20
M) (34) and NTPDase 3 (ATP, 98 M; ADP, 128 M) (35).
We recently demonstrated that NSAP is the alkaline phos-
phatase isoform functionally expressed by human airway epi-
thelia (13). Clinical assays, generally performed in basic solu-
tions (pH 9–10), depict NSAP as a low affinity enzyme (KM
400M) (23).However,NSAPhas been shown to exhibit both
low (lowNSAP; KM 400 M) and high (highNSAP; KM 
TABLE 1
Kinetic parameters of ASL nucleotide/nucleoside release, uptake, and metabolism measured on primary cultures of HBE cultures or estimated
by the model equations without/with ADP and AMP release
Unknown experimental values are labeled Unk. The units for Vmax or J/V are nmol  min1  ml1, and the units for KM are M.
1 REF indicates references for the experimental data from our previous studies.
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12–20 M) affinities for adenine nucleotides at pH 7.5 (36–38).
We reported that airway NSAP hydrolyzes AMP with KM val-
ues of 36 M (highNSAP, KM(7); Table 1, column A) and 717 M
(lowNSAP, KM(8)KM; Table 1, column A) at pH 7.5 (13). Because
the kinetic parameters of airway NSAP for ATP and ADP were
unavailable, we conducted these experiments, as described pre-
viously (13) but in the presence of the ecto-AK inhibitor, Ap5A
(28). Two kinetic parameter sets were identified for ATP and
ADP hydrolysis (Table 2), with KM values within the ranges
reported for lowNSAP and highNSAP activities (36–38).
These values also approximated the KM values of the high
affinity and low affinity ecto-ATPase (KM(1) andKM(3)) and ecto-
ADPase (KM(4) and KM(5)) activities (Table 1, column A).
Because NSAP, NTPDase 1, and NTPDase 3 all support the
dephosphorylation of ATP and ADP, enzyme activities with
similar KM values were combined and designated as the high
affinity (NTPDase 1/highNSAP) and the low affinity (NTPDase
3/lowNSAP) enzymes (Table 1, column A).
The list of experimental data were completed by adding the
kinetic parameters of ADA1 (29), the cellular uptake of Ado by
CNT3 (29), the basal rate of ATP release (12), and the feed-
forward inhibition of Ado production by ATP and ADP (13).
Altogether, these assays and studies provided the experimental
data set that was used to develop the mathematical model of
nucleotide regulation on human airway epithelia (Table 1, col-
umn A).
Model Validation with Experimental Data—The model was
tested by comparing simulated and previously reported exper-
imental measurements of transient (26) and steady-state (12)
nucleotide and nucleoside concentrations on the apical surface
ofHBE cells.We started our investigations using themulticom-
ponent model (Fig. 1) described by Equations 7–11. Experi-
mental values were available for all parameters from earlier
studies (Table 1), except the KM of ecto-AK for AMP and the
KM andVmax values of CNT3 for Ino.When used as free param-
eters to fit the data, considerable discrepancies were found
between the simulated and experimental transient profiles of
ATP hydrolysis (Fig. 2A) and steady-state concentrations (Fig.
2B). The performance of the model was considerably improved
by using the experimental data set as initial guesses in the non-
linear least square fitting routine in MatLab (Mathworks,
Natick, MA). Using this approach, the model closely repro-
duced the transient and steady-state profiles (Fig. 2, C and D).
Among the 30 estimated parameters, only 6 were 2-fold dif-
ferent from the experimental values (Table 1, column B) as
follows: high affinity ecto-ATPase (Vmax(1) ), E-NPPs (Vmax(10) and
KM(10)), ecto-AK (Vmax(f) ) and the feed-forward inhibition con-
stants (KATP(in) and KADP(in) ). However, a 12-fold discrepancy per-
sisted betweenmeasured and predictedATP release rates. Sim-
ilar experimental values were reported by different research
groups using various techniques (10, 12, 20), ruling out experi-
mental error as the source of discrepancy. On the other hand, if
the rate of ATP release was held fixed at the experimental value
and the other parameters free to be determined by data fitting,
FIGURE 1. Diagram of adenine nucleotides transport and metabolism on
human bronchial epithelia. Released by the epithelium, ATP is sequentially
dephosphorylated into Ado by E-NPPs, ecto-AK, NTPDase 1, NTPDase 3,
NSAP, and ecto-5-NT. Ado is converted into Ino by ADA1, both returning to
the cytosol via CNT3. The model also includes the feed-forward inhibition of
Ado production by ATP and ADP.
FIGURE 2. Validation of the transient and steady-state concentration pro-
files generated by the nonlinear model without data fitting (A and B) or
by data fitting using the MatLab nonlinear least square program without
(C and D) or with (E and F) JATP fixed at the experimental value. A, C, and E,
simulation (lines) and experimental data (symbols; n  5; S.E. 
10% of mean)
for nucleotide/nucleoside concentrations measured by HPLC of buffer sam-
ples collected from HBE cultures after the addition of 100 M ATP (n  6). B, D,
and F, steady-state concentrations obtained by model simulation (empty
bars) and experimental data (filled bars) from previous publications by our
group (n  5; 	S.E.) (12, 26).
TABLE 2
Kinetic parameters of ATP and ADP dephosphorylation by NSAP on
primary cultures of HBE cells
Michaelis constants (KM; M) and maximal velocities (Vmax: nmol  min1  ml1)
were calculated fromWoolf-Augustinson Hoftsee plots.
Reactions Enzyme identity Parameters Experimental data
ATP3 ADP  Pi HighNSAP Vmax, KM 1.0, 17
LowNSAP Vmax, KM 14.1, 451
ADP3 AMP  Pi HighNSAP Vmax, KM 0.5, 11
LowNSAP Vmax, KM 5.9, 117
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themodel reproduced the transient behavior of the system (Fig.
2E) but not the steady-state profile (Fig. 2F).
Steady-state Analysis with a Linear Model—In an attempt to
resolve the differences between experimental and predicted
steady-state ATP concentrations, we developed a linear model
to describe the system near steady state, as described by Equa-
tions 13–17. The model was analyzed using two strategies.
First, the experimental steady-state concentrations were used
as inputs, and the model was solved for the parameter values.
Because the steady-state Ino level cannot be measured by fluo-
rescent HPLC, it was considered an unknown value in this pro-
cedure. In this case, solving the linear equations generated a
negative Ino concentration, which is biologically impossible.
Second, the experimental data set (Table 1, columnA)was used
as input parameters, and the model was solved for the steady-
state concentration profile. This approach generated a good
approximation of the experimental ATP concentration, but it
resulted in estimated ADP, AMP, and Ado levels 10-fold
lower than the experimental values (Table 3). Altogether, these
results suggested that the model was incompatible with the
experimental data and was therefore missing key components.
Our current knowledge on nucleotide release is limited to
ATP because the inhibitor mixture designed to prevent nucle-
otide metabolism (20) interferes with fluorescence HPLC.
However, emerging studies suggest that exocytosis mediates
the release of ATP, ADP, andAMP frommammalian cells (39–
41), including polarized epithelia (4, 7, 42). We recently dem-
onstrated that human airway epithelia co-release ATP and
mucin by Ca2-regulated exocytosis (42). During their matura-
tion, secretory vesicles accumulate ATP- and UDP-sugars in
concentrations 50-fold above cytosolic levels, a fraction of
which is converted to ADP and UDP, and eventually to AMP
and UMP (40). As a result, vesicle fusion to the apical mem-
brane is expected to release ATP, ADP, and AMP into the ASL
layer. These observations motivated the addition of terms
describing ADP and AMP release to the mathematical model.
Constant fluxes for ADP (JADP) and AMP (JADP) were added to
the linear equations (Equations 13–17), and the values were
adjusted so the model would generate steady-state concentra-
tions closest to the experimental values. Table 3 shows that
adding ADP and AMP release to the model eliminated the dis-
crepancies between the experimental and predicted steady-
state concentration profiles.
Reanalysis of theNonlinearModel—Themultienzymemodel
with the nonlinear equations (Equations 7–11) was updated to
include terms describing the release of ADP (JADP/V in Equa-
tion 8) and AMP (JATP/V in Equation 9). The model was then
refitted using the experimental data set (Table 1, columnA) and
the parameters of JADP and JAMP (Table 1, column C). Under
these conditions, the simulations closely reproduced the exper-
imental transient (Fig. 3A) and steady-state (Fig. 3B) concentra-
tion profiles, and eliminated the 12-fold difference between
measured and estimated JATP. Finally, the predicted Vmax and
KM values (Table 1, column C) were in closest agreement with
the experimental data (Table 1, column A). Collectively, these
simulations and experiments suggest that the model captures
all major elements of nucleotide regulation on human airway
epithelia.
Impact of ASLVolume onNucleotide Regulation—Themodel
identified an important property of airway nucleotide regula-
tion regarding ASL volume, which has been identified as a key
determinant of mucus clearance (1, 2). Because the rate at
which ATP release raises ATP concentration (JATP) and the
maximum reaction velocity (Vmax  (kcatA)/(V)[E]T), both
scale inversely with ASL volume in Equation 6, the model pre-
dicts that steady-state concentrations are independent of ASL
volume. Following a simulated 2-fold increase in ASL volume,
which acutely dilutes ATP andADP, nucleotide concentrations
FIGURE 3. Validation of the transient and steady-state concentration pro-
files generated by the model equations, including basal rates of ADP and
AMP release. A, simulated (lines) and experimental (symbols; n  5; S.E. 
10%
of mean) transient nucleotide/nucleoside concentration profiles generated
by the addition of 100 M ATP on HBE cultures. B, simulated (empty bars) and
experimental (filled bars) steady-state concentration profiles from previous
publications by our group (n  5; 	S.E.) (12, 26).
TABLE 3
Steady-state concentrations (nM) calculated from the linear model
without or with parameters of ADP and AMP release
Unk indicates unknown.
ATP ADP AMP Ado Ino
Experimental data 2.2 38.7 70.2 168 Unk
Model optimization (JATP) 3.9 2.8 4.6 15.3 6.7
Model optimization (JATP, JADP, JAMP) 4.0 38.1 70.3 231.7 102.0
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are predicted to rapidly return to steady-state values (Fig. 4A).
These simulation data were validated experimentally on HBE
cultures using two luminometry assays, soluble luciferase and S.
aureus protein A-luciferase attached to the epithelial surface.
Fig. 4B shows that steady-state ATP and ADP levels, measured
60 min after the addition of 10–500 l of phosphate-buffered
saline, were unaffected by ASL volume changes. This result
provides new insights into the biochemical processes support-
ing MCC. For instance, the airways of CF patients exhibit an
70% reduction in ASL volume, which plays a critical role in
airway obstruction (1, 2). Under steady-state conditions, the
model predicts that ASL dehydration in CF does not concen-
trate, i.e. increase the availability of ATP and Ado for P2 and P1
receptor-mediated mucus clearance as a compensatory mech-
anism to restore ASL volume.
Model Adaptation to Mechanical Stress—Normal tidal
breathing applies compressive and shear stresses on the airway
walls that stimulate epithelial ATP release and ATP-mediated
MCC (8, 10). This physiological response is particularly rele-
vant to airway homeostasis as CCS mimicking tidal breathing
was shown to restore ASL volume and mucus transport on the
dehydrated airways of CF patients (10). Because themathemat-
ical model was developed using experimental data acquired on
static cultures, we tested its capacity to predict the ASL nucle-
otide and nucleoside concentrationsmaintained bymechanical
stress mimicking tidal breathing. We recently demonstrated
that CCS increases the rate of ATP release by 9.3-fold on HBE
cultures (10). In this study, we conducted experiments to test
the impact of CCS on the entire steady-state nucleotide con-
centration profile. Fig. 4C shows that CCS raised ATP, ADP,
AMP, and Ado concentrations by 4–8-fold within the ASL
layer.Model simulationswere conducted to determinewhether
this response tomechanical stress was best fitted by an increase
in the rate of ATP release or by concomitant increases in the
release of several nucleotides. The equations solved with a 9.3-
fold higher rate of ATP release (JATP; Table 1, columnC) repro-
duced the effect of CCS on ATP but not on ADP or AMP (Fig.
4C). This simulation suggested that ATP release and metabo-
lismwere unable to account for the impact of CCS on ADP and
AMP levels. Simultaneous 9.3-fold increases in JATP and JADP
generated ATP and ADP levels within experimental range,
whereas AMP levels remained 2-fold lower. The impact of
CCS on the ASL concentration profile was best fitted by a
model simulation inwhich JATP, JADP, and JAMPwere all 9.3-fold
higher than base line. Altogether, these data are consistent with
the general proposal that mechanical stress induces the release
of all three nucleotides through exocytosis in polarized epithe-
lia (39–42). Furthermore, they demonstrate the ability of the
mathematical model to predict the complex behavior of ASL
nucleotide regulation under static and dynamic conditions.
NovelApproach toBiochemicalNetworkAnalysis—Although
several ectonucleotidases have been characterized on the apical
surface of HBE cells (13–15, 24–29), the key enzyme(s) regu-
lating nucleotide-mediated MCC remain unidentified because
of the complexity of themultienzyme network. Themathemat-
ical model allowed us, for the first time, to determine the con-
tribution of each enzyme and enzyme group to the regulation of
both physiological and pathological ASL nucleotide concentra-
FIGURE 4. Modeling the impact of ASL volume and mechanical stress
mimicking tidal breathing on ASL nucleotide regulation. A, model simu-
lation of the impact of increasing ASL volume by 2-fold (20 l) on steady-state
ATP/ADP concentrations. B, model validation by biochemical measurements
of steady-state ATP concentration using soluble luciferase (solid black box) or
cell-attached S. aureus protein A-luciferase (open box) on HBE cultures after
the addition of 1–500 l of phosphate-buffered saline (n  5; 	S.E.). C, impact
of CCS (solid red box) on the steady-state concentration profile. HBE cultures
were exposed 1 h to static conditions (control) or CCS mimicking tidal breath-
ing (20 cm H2O; 20 cycles/min) (10). Then ASL nucleotide concentrations were
measured by HPLC (n  7; 	S.E.). Model simulations conducted to reproduce
the impact of CCS on the steady-state concentration profile by increasing the
release rates of ATP (JATP; black box), ATP and ADP (JATP, ADP; striped box) or
ATP, ADP and AMP (JATP, ADP, AMP; open box) by 9.3-fold (10). Values expressed
as fold increase from static exposure.
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tions. Several airway ectonucleotidases have been shown to
hydrolyze ATP, ADP, and/or AMP as follows: NTPDase 1,
NTPDase 3, NSAP, E-NPPs, and ecto-AK (14, 15, 28). Based on
their kinetic properties, we hypothesized that specific enzymes
regulate ASL nucleotide levels encountered under physiologi-
cal conditions (
0.1 M) (8, 12, 20), whereas others regulate
higher ASL concentrations reached during tissue injury (0.1–1
M) (43–46) or aerosolization (1–100 M) for diagnostic (47,
48) or therapeutic (49–52) purposes. The biochemical network
was first simplified by classifying the enzymes into the following
two groups: 1) low affinity high capacity (KM  50 M; NTPDase
3, lowNSAP), and 2) high affinity low capacity (KM 
 50 M;
NTPDase 1, E-NPPs, highNSAP, and ecto-AK). Model simula-
tions were conducted by blocking the Vmax of each enzyme
(Table 1, column C) to reproduce the effects of selective inhib-
itors on HBE cultures. One of them, levamisole, inhibits both
the high and low affinity activities of NSAP (13), which could
introduce validation errors into group comparisons. This pos-
sibility was addressed by comparing the impact of eliminating
highNSAP, lowNSAP, or high/low NSAP activities on ASL
nucleotide regulation within the two concentration ranges of
interest: aerosolized/pathological (10–100 M) and physiolog-
ical (0.1–1 M). For Vmax values corresponding to the total
maximum activities of two enzymes, NTPDase 1/highNSAP
(Vmax(1) andVmax(4) ) andNTPDase 3/lowNSAP (Vmax(5) ),NSAPactiv-
ity was blocked by reducing the estimated parameter (Table 1,
column C) proportionally by its experimental contribution
(Table 2) to total enzyme activity (Table 1, column A). Fig. 5A
shows that blocking highNSAP reduced the elimination rate of
100 MATP by 
10%. In contrast, blocking lowNSAP or high/
lowNSAP reproduced the effects of 10 mM levamisole on the
HBE cultures and increased the half-life (t1⁄2) of 100 M ATP by
1.6-fold. Conversely, the metabolism of 1 M ATP was not
affected by blocking lowNSAP, whereas blocking highNSAP or
high/lowNSAP mimicked the effects of levamisole with a 1.9-
fold increase in the t1⁄2 of ATP (Fig. 5B). These data indicate that
lowNSAP and highNSAP activities exhibit negligible overlap,
regulating excess and physiological ATP concentrations selec-
tively. Consequently, model simulations in which both NSAP
activities are blocked are expected to reproduce the effects of
levamisole within the concentration range of interest.
We first acquired general information on the biochemical
network by comparing the relative contribution of the low
affinity and high affinity enzyme groups to the regulation of
aerosolized/pathological nucleotide concentrations. Model
simulations in which the kinetic parameters of the low affinity
enzymes (high/lowNSAP and NTPDase 3) were blocked pre-
dicted a 4-fold decrease in elimination rate of 100 M ATP and
significant delays in the accumulation of ADP, AMP, and Ado
(Fig. 5C). Comparable profiles were obtained experimentally
using HBE cultures assayed with 100 M ATP in the absence
(control) or presence of an inhibitormixture specific for the low
affinity enzymes (Fig. 5C) as follows: 10 mM levamisole (NSAP)
(13)  10 M NF-279 (NTPDase 3) (53). In contrast, model
simulation in which all the high affinity enzymes (high/low-
NSAP, NTPDase 1, E-NPPs, and ecto-AK) were blocked
yielded minor modifications in the transient profile, with a 1.5-
fold decrease in elimination rate of 100 M ATP (Fig. 5D).
Although experimental validation of the high affinity block
awaits the identification of noncompetitive inhibitors for
NTPDase 1 and E-NPPs, these data suggest that high ATP
levels (10 M) are regulated mainly by the low affinity
enzymes on airway epithelia.
Comparative analyses conducted over a broad range of ATP
concentrations predicted a shift in the relative contribution of
the high and low affinity enzyme groups. To carefully scrutinize
the involvement of each group, the two NSAP activities were
analyzed independently. Model simulations in which the high
affinity enzymes (highNSAP, NTPDase 1, E-NPPs, and ecto-
AK) or the low affinity enzymes (lowNSAP and NTPDase 3)
were blocked raised the t1⁄2 of 100 M ATP by 1.2- and 2.3-fold,
respectively (Fig. 5E). Although the t1⁄2 of 10 M ATP would be
equally affected by either group, the high affinity group is pre-
dicted to dominate at lower ATP concentrations. These simu-
lationswere reproduced experimentally onHBE cultures with a
FIGURE 5. Contribution of the low affinity and high affinity enzyme
groups to ASL nucleotide regulation. A and B, simulations comparing
hydrolysis rates of 100 M ATP (A) or 1 M ATP (B) under control conditions
(solid black line) or after blocking highNSAP (solid red line), lowNSAP (solid blue
line), or both (high/lowNSAP) (dashed blue line). Validation conducted on HBE
cultures for control conditions (F) and high/lowNSAP inhibition by 10 mM
levamisole (open blue box). C and D, simulated metabolic profile for 100 M
ATP before (solid line) and after (dashed line) blocking the low affinity (LA;
lowNSAP and NTPDase 3) (C) or high affinity (HA; NTPDase 1, highNSAP,
E-NPPs, and ecto-AK) enzymes (D). Validation for the control (C and D, filled
symbols) and low affinity block (C; open symbols) using an inhibitor mixture
(10 mM levamisole  10 M NF-279) (n  5; S.E. 
10% of mean). E, simulated
half-life (t1⁄2) of 0.1–100 M ATP generated by blocking the high affinity (solid
black box) or low affinity (striped box) group, and experimental data (solid red
box) for the low affinity block as above (n  5; 	S.E.). F, simulated impact of
blocking the high affinity (solid black box) or low affinity (striped box) group on
the steady-state profile. Validation (solid red box) was by comparing ASL
nucleotide levels before/after incubating HBE cultures with the low affinity
inhibitor mixture (n  5; 	S.E.).
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low affinity inhibitor mixture (10 mM levamisole  10 M
NF-279) (Fig. 5E). The model suggests that the higher contri-
bution of the low affinity group measured experimentally for
0.1 M ATP reflects the inhibitory effect of levamisole on
highNSAP. Together, simulated and experimental results sup-
port a major role for high affinity enzymes in the regulation of
ASL ATP within the effective concentration range of P2Y2
receptors (0.01–1 M) (16, 17).
Recent studies showed that ASL nucleotide metabolism is
accelerated in chronic lung diseases, including CF, chronic
obstructive pulmonary disease, and primary ciliary dyskinesia
(14), which could compromise nucleotide-mediated MCC (19,
52). Consequently, activation of P2Y2 receptors by aerosolized
nucleotides is being tested as a therapy for CF (52, 54). As an
alternative strategy to raise steady-state ASL ATP concentra-
tion, we conducted simulations to test the potential of an aero-
solized inhibitormixture against specific enzymes. As expected
from their kinetic properties, model simulations in which the
low affinity enzymes (lowNSAP and NTPDase 3) were blocked
predicted a
2-fold increase in steady-state nucleotide concen-
trations (Fig. 5F). This simulation was reproduced experimen-
tally by assays conducted on HBE cultures exposed to the low
affinity inhibitor mixture (10 mM levamisole  10 M NF-279)
(Fig. 5F). Because levamisole does not discriminate between the
lowNSAP and highNSAP activities, these assays demonstrate
that NSAP does not contribute significantly to the regulation of
steady-state ATP concentrations (i.e. 
0.1 M) on airway epi-
thelial surfaces. To our surprise, the model predicts that the
steady-state nucleotide levels are sensitive to the high affinity
enzyme groupwith respect toADPbut notATP (Fig. 5F), which
suggested the influence of a nonlinear component within the
biochemical network.
The properties of the reversible ecto-AK reaction suggest
that the net directionality depends on the relative substrate
concentrations (Fig. 6A). Micromolar ATP, encountered dur-
ing injury or aerosolization, would drive the forward reaction,
whereas steady-state conditions would favor the reverse reac-
tion because of the relatively highADP concentration (Table 3).
Therefore, simulations and assays were designed to test
whether ecto-AK influences the ATP/ADP concentration ratio
on airway epithelial surfaces in these two situations (Fig. 6A).
Model simulations predicted that blocking ecto-AK would not
affect the metabolism of 100 M ATP (Fig. 6B) or the steady-
state concentration profile (Fig. 6E). These simulated data were
reproduced experimentally for the transient (Fig. 6B) and
steady-state (Fig. 6E) concentration profiles by HBE cultures
exposed to the vehicle control or buffer containing the ecto-AK
inhibitor, 0.5mMAp5A (28).We next tested the hypothesis that
ecto-AK activity may be significant within a functional unit
addressing a specific nucleotide concentration range. Fig. 6C
shows that blocking ecto-AK is not expected to influence the
metabolic profile of 100 M ATP regulated by the low affinity
enzymes, i.e. determined in the absence of the other high affin-
ity enzymes. In contrast, model simulations and experimental
data suggest that ecto-AK contributes to the regulation of ASL
nucleotides under conditions where the high affinity enzyme
activities predominate. First, the model predicts that blocking
ecto-AK would not affect the elimination rate of 100 M ATP
by a high affinity biochemical network, i.e. determined in the
absence of the low affinity enzymes (Fig. 6D). However, when
ADP concentration rises above that of ATP (20 min), the
absence of ecto-AK would be associated with higher rates
of ADP elimination and Ado accumulation (Fig. 6D). Similar
results were obtained experimentally with HBE cultures using
the low affinity inhibitor mixture (10 mM levamisole and 10 M
NF-279) with/without 0.5 mM Ap5A (Fig. 6D). These data were
also consistent with the behavior of ecto-AK reported on HBE
cultures exposed to an ATP concentration (1 M) (28) pre-
dicted to be regulated predominantly by high affinity enzymes
(Fig. 5E). The reverse ecto-AK reactionwould competewith the
high affinity ADP-hydrolyzing enzymes to trap adenine nucle-
otides into a trans-phosphorylation cycle (28). These findings
suggest that airway ecto-AK regulates ASL nucleotide levels
within a high affinity biochemical network exposed to a high
ADP/ATP concentration ratio.
Based on this information, we revisited the impact of
ecto-AK on ASL nucleotide regulation at steady-state condi-
tions, which is expected to favor the reverse ecto-AK reaction
(2ADP3ATPAMP) (Fig. 6A) because of the highADP/ATP
ratio (20; see Table 3). Amodel simulationwith a high affinity
inhibitor mixture, excluding the ecto-AK inhibitor, resulted in
a 6-fold increase in steady-state ATP concentration (Fig. 6E),
FIGURE 6. Role of ecto-AK in ASL nucleotide regulation. A, reaction direc-
tionality during nucleotide aerosolization (10 M ATP) and under steady-
state conditions (1–10 nM ATP) with ADP/ATP 20 (Table 3). B–D, simulations
(lines) of the impact of blocking ecto-AK on the metabolism of 100 M ATP
(B) in the presence of all enzymes and after blocking (C) the high affinity
(NTPDase 1, highNSAP, and E-NPPs) or (D) low affinity (LA; lowNSAP and
NTPDase 3) enzymes. B, validation using HBEs pretreated with the vehicle
(closed symbols) or the ecto-AK inhibitor (0.5 mM Ap5A; open symbols). D, val-
idation on HBEs pretreated with the low affinity inhibitor mixture (10 mM
levamisole  10 M NF-279) without (closed symbols) or with (open symbols)
0.5 mM Ap5A (n  6; S.E. 
 10% of mean). E, impact of blocking ecto-AK on the
steady-state profile by stimulation (solid black box) or exposing HBEs to 0.5
mM Ap5A (solid red box) (n  5; 	S.E.). Data were compared with the simulated
impact of blocking the other high affinity enzymes (open box).
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compared with 2-fold for a complete high affinity block (Fig.
5F). The physiological relevance of this information is illus-
trated by the fact that a comparable increase in ASL ATP level
was generated by CCS mimicking normal tidal breathing (Fig.
4C), which restorednormalASLheight andmucus transport on
the dehydrated airway epithelial surfaces of CF patients (10).
The mathematical model of ASL nucleotide regulation there-
fore identified the key enzymes regulating ASL ATP and pro-
poses a novel approach for the treatment of airway obstruction
in CF, an aerosolized inhibitor mixture against high affinity
NTPDase 1 and E-NPPs.
Adenosine Regulation in Airway Defenses—The model was
instrumental to our investigation of airway Ado regulation,
supplementing the biochemical assays with simulated informa-
tion that would not be available experimentally. First, we mod-
eled the relative contribution of the two ectonucleotidases sup-
porting the conversion of AMP to Ado on airway epithelial
surfaces, NSAP and ecto-5-NT (13). Model simulations were
run by blocking the parameters of the following: 1) ecto-5-NT;
2) high/lowNSAP toward AMP [NSAP (AMP)], or 3) high/
lowNSAP toward ATP, ADP, and AMP [NSAP (all)]. These
simulations were verified by biochemical assays conducted on
HBE cultures before and after the inhibition of ecto-5-NT (10
mM concanavalin A) (13, 55) or NSAP (10 mM levamisole) (13,
56). Although blocking all parameters of NSAP would mimic
the effects of levamisole, we tested whether the concomitant
reductions in ecto-ATPase and ecto-ADPase activities would
influence the feed-forward inhibition of Ado accumulation
(Equation 3) (13). Hence, all simulations and assays were initi-
ated with ATP to probe the response of the entire biochemical
network.
Comparative analysis conducted over a range of ATP con-
centrations revealed a shift in the relative contribution of ecto-
5-NT andNSAP (Fig. 7,A–C). Both simulated and experimen-
tal data showed that ecto-5-NT dominates at physiological
ATP levels (0.1–1.0M), as indicated by larger reductions in the
accumulation rate of Ado (Fig. 7, A and B). In contrast, Ado
production from 10 M ATP would be equally reduced by
blocking ecto-5-NT or NSAP (AMP) (Fig. 7C). Interestingly,
an intermediate response was predicted by blocking NSAP (all)
(Fig. 7C) or measured experimentally with levamisole (Fig. 7C).
These data suggest that levamisole increases the availability of
ATP and ADP for the feed-forward inhibition of Ado produc-
tion by the remaining enzyme, ecto-5-NT.
Model simulations were designed to evaluate the physiolog-
ical relevance of feed-forward inhibition for airway homeosta-
sis by calculating the time required for 1–1000 MATP to gen-
erate an Ado concentration equivalent to the EC50 of A2B
receptors (0.3 M) (16, 17). Both simulated and biochemical
data demonstrated that the delay to reach 0.3 M Ado is influ-
enced by theASLATP concentration in a biphasicmanner (Fig.
7D). A relatively long delay would be expected for concentra-
tions (i.e. 1MATP) below the catalytic capacity ofmost airway
ectonucleotidases (Table 1, column A). In the 10–100 MATP
range, both enzymes efficiently converted AMP to Ado,
whereas longer delays are required for ATP levels challenging
their Vmax.
The mathematical model was able to identify the enzyme
targeted by feed-forward inhibition using simulations that can-
not be reproduced experimentally: by blocking the kinetic con-
stants (KATP(in) and KADP(in) ; Table 1, column C). We compared the
impact of blocking each AMP-hydrolyzing enzyme on the
ATP-mediated regulation of Ado production in the presence or
absence of feed-forward inhibition.Model simulations inwhich
the Vmax of ecto-5-NT activity was blocked resulted in slightly
longer Ado delays (
 30%) at all ATP concentrations, which
were partially reduced to control values by blocking the inhibi-
tion constants (Fig. 7D). These simulations predict a weak con-
trol of feed-forward inhibition over the remaining enzyme,
NSAP, which may be ascribed to its capacity to eliminate ATP
and ADP in close vicinity to the catalytic site.
The reciprocal simulation exposed a strong relationship
between ASL ATP concentration and Ado production by ecto-
FIGURE 7. Relative contribution of ecto-5NT and NSAP to Ado regulation.
A–C, simulated (lines) and experimental (symbols) time courses of Ado accu-
mulation from 0.1 to 10 M ATP under control conditions and after blocking
ecto-5-NT (solid red line) or NSAP (solid blue line) activities. For NSAP, simula-
tions were run by blocking the parameters regulating AMP (NSAP (AMP))
(dashed blue line) or all nucleotides (NSAP (all)) (solid blue line). Experimental
data using HBE cultures were incubated with 0.1–10 M ATP, without/with an
inhibitor of ecto-5-NT (10 mM concanavalin A) (open red triangle), or NSAP
(all) (10 mM levamisole) (open blue box) (n  6; S.E. 
 10% of mean). D, simu-
lated (solid black box) and experimental (solid red box) delay to the accumula-
tion of 0.3 M Ado from 1 to 1000 M ATP. Simulations also compared the
impact of blocking ecto-5-NT with (striped box) or without (open box) feed-
forward inhibition (KATP
(in) , KADP
(in) block; Table 1, column C). E, simulated (solid
black box) and experimental (solid blue box; n  5, p 
 0.05) impact of blocking
NSAP (all) on the delay to reach 0.3 M Ado (fold from controls in D). Simulated
impact of blocking both NSAP (all) and feed-forward inhibition (striped black
box) is shown. F, simulated impact of blocking NSAP (all) (solid black box) or
ecto-5-NT (open box) on the steady-state profile. Experimental block of NSAP
(all) (solid blue box) or ecto-5-NT (solid red box) was obtained by measuring
nucleotide levels before/after incubating cultures with the inhibitors (n  5,
p 
 0.05).
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5-NT. The time required for Ado to reach the EC50 of A2B
receptors (0.3 M) (16, 17) increased by up to 6-fold when ecto-
5-NTdominated, i.e. in the absence ofNSAP, with a regulatory
threshold of 1MATP (Fig. 7E). These simulations were repro-
duced by HBE cultures pretreated with the NSAP inhibitor (10
mM levamisole). The model predicts that this relationship
would be completely abrogated by simultaneously blocking
NSAP (all) and the feed-forward inhibition (Fig. 7E). Themath-
ematical model therefore provided new insights into the bio-
chemical processes regulating ASL Ado, which would not have
been available otherwise. The simulations predict that feed-
forward inhibition targets specifically Ado production by ecto-
5-NT on HBE surfaces. However, whereas the sensitivity of
ecto-5-NT activity to 1 M ATP is consistent with the prop-
erties of the vascular model of nucleotide regulation (57–59),
airway epithelia seldom experience such high ATP concentra-
tions, except locally during injury or aerosolization.
Finally, we determined the contribution of NSAP and ecto-
5-NT to the regulation of the steady-state nucleotide concen-
trations. The model predicts that NSAP inhibition would raise
ATP, ADP, and AMP concentrations by 1.4-, 2.5-, and 2.8-fold,
respectively (Fig. 7F). This inverse relationship between NSAP
activity and the degree of phosphorylation of the substrate was
closely reproduced experimentally by levamisole on HBE cul-
tures (Fig. 7F) and is consistent with the properties of the puri-
fied enzyme: ATP 
 ADP 
 AMP (60, 61). In contrast, model
simulations in which ecto-5-NT activity was eliminated only
increased AMP concentration, in agreement with the substrate
specificity of the enzyme (56). These results were reproduced
by HBE cultures exposed to the selective inhibitor, concanava-
lin A (Fig. 7F). Altogether, these data demonstrate that the
model captures the contributions of ecto-5-NT and NSAP to
the regulation of steady-state nucleotide concentrations. On
the other hand, inhibiting ecto-5-NT or NSAP did not influ-
ence the steady-state concentration ofAdo, which suggests that
one AMP-hydrolyzing enzyme may be sufficient under condi-
tions where AMP concentration is 100-fold lower than their
KM values.
DISCUSSION
This study presents the firstmathematicalmodel of extracel-
lular nucleotide and nucleoside regulation for the respiratory
system. Based on experimental data reported in the literature
(12, 13, 20, 26, 28, 29), and acquired in this study, for polarized
HBE cultures, Equations 7–11 were designed to incorporate all
known factors regulating ASL nucleotides and Ado as follows:
epithelial ATP release, the reactionsmediating the surface con-
version of ATP into ADP, AMP, and Ado, the surface elimina-
tion ofAdo by deamination and cellular uptake, the trans-phos-
phorylating ecto-AK activity, and the feed-forward inhibition
of Ado production by ATP and ADP. The simulations closely
reproduced the transient and steady-state concentration pro-
files generated on the apical surface following the addition of
ATP. However, regardless of the fitting strategy, a 12-fold dif-
ference persisted between the simulated and experimental rates
of ATP release, suggesting themodel wasmissing key elements.
The current information on the mechanisms of nucleotide
release is derived from measurements of ATP release (62, 63).
Yet recent breakthroughs in our understanding of exocytosis
support the notion that nucleotides, in addition toATP, are also
released via this route by a variety of cell types (4, 39–41),
including HBE cells (42). During their maturation, the vesicles
accumulate ATP, ADP, and AMP, which are released during
exocytosis (39–41). Importantly, the addition of terms describ-
ing ADP and AMP release provided the best fit of the experi-
mental data, as well as the transient and steady-state concen-
tration profiles. Furthermore, it resolved the discrepancy
between simulated and experimental rates of ATP release.
The resulting model was validated by testing the impact of
mechanical stress onASLnucleotide regulation.Airway epithe-
lia, in vivo, are subjected tomechanical forces imparted by tidal
breathing, which are known to stimulate ATP release (8, 10).
We recently showed that CCS mimicking normal tidal breath-
ing causes a 9.3-fold increase in the rate of ATP release from
HBE cultures (10). In this study, we showed that CCS raises the
ASL concentrations of ATP, ADP, AMP, and Ado by 4–7-fold.
Model simulations in which JATP was increased 9.3-fold repro-
duced the effects of CCS on ATP but not on the other nucleo-
tides. The model therefore predicted that mechanical stress-
induced ATP release and surface metabolism are unable to
account for the effects of CCS on the ASL nucleotide composi-
tion. In fact, the best fit was obtained by raising simultaneously
JATP, JADP, and JAMP by 9.3-fold. These results support the
importance of including parameters for the release of all three
nucleotides into the mathematical model of ASL nucleotide reg-
ulation. Furthermore, they illustrate the capacity of the model to
predict the impact of physiological phenomena such as breathing
on ASL nucleotide regulation.
Multiple ATP-hydrolyzing enzymes compete for the same
pool of nucleotides within the ASL layer. The development of a
mathematical model incorporating all the ectonucleotidases
provided, for the first time, an invaluable tool to assess their
individual contribution within the multienzyme system. The
complex biochemical network was simplified by sorting the
enzymes into kinetically distinct groups as follows: low affinity
high capacity (KM  50 M; lowNSAP and NTPDase 3) and
high affinity low capacity (KM
 50M; highNSAP, E-NTPDase
1, E-NPPs and ecto-AK) (26, 64). Model simulations accurately
predicted the predominant role of the low affinity group in the
regulation of high ATP concentrations (1 M) (43–46), as
demonstrated on HBE cultures using selective inhibitors of
NSAP (10mM levamisole) (13) andNTPDase 3 (10MNF-279)
(53). Therapies inhibiting these ectoenzymes could potentially
accentuate airway epithelial apoptosis (65, 66) and inflamma-
tory responses (45) because of increased ATP-mediated activa-
tion of P2X7 receptors, which are up-regulated in lung diseases
(67). In addition, these enzymes are likely responsible for the
rapid elimination of aerosolized nucleotides (1–100 M)
used to diagnose asthma and chronic obstructive pulmonary
disease (ATP and AMP) (47, 48), for the treatment of CF and
primary ciliary dyskinesia (UTP) (49–52) and in animal
studies (48, 68, 69).
The model predicts that high affinity enzymes play a major
role in the regulation of ATP within the physiological concen-
tration range encountered on airway epithelial surfaces (8, 12,
20). The recent report that CCS-mediated increase in ASLATP
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level restores ASL volume and mucus transport on dehydrated
HBE cultures fromCF patients (10) motivated the search for an
inhibitor mixture against the high affinity enzymes to enhance
P2Y2 receptor-mediatedmucus clearance. However, themodel
predicts that blocking all four enzymes would raise ADP con-
centrations, instead of ATP. An explanation was provided by
separating the high affinity enzymes into linear and nonlinear
components. Inhibition of the enzymes supporting the linear
reactions (ATP 3 ADP 3 AMP; NTPDase 1, E-NPPs and
highNSAP) is expected to raise the concentrations of all the
released nucleotides. In contrast, the directionality of the
reversible ecto-AK reaction (ATP  AMP7 2ADP) would be
influenced by the ASL nucleotide composition. Model simula-
tions and biochemical assays suggest that ecto-AK does not
influence the elimination of high ATP concentrations (10
M). However, blocking ecto-AK significantly modified the
transient metabolic profile generated by the high affinity
enzyme group once ADP level exceeded that of ATP by
3-fold, as depicted by enhanced ADP, but increased Ado,
accumulation. This behavior is consistent with the substrate
requirements of the reversible ecto-AK reaction. The for-
ward reaction (ATP  AMP 3 2ADP) is limited on airway
epithelia by the high ATP/AMP ratio maintained through
efficient conversion of AMP to Ado. In contrast, the reverse
reaction (2ADP3 ATP  AMP) is favored once ADP con-
centration exceeds that of [ATP  AMP]. However, the ATP
generated by ecto-AK would be rapidly dephosphorylated by
the high affinity ecto-ATPases (NTPDase 1, E-NPPs, and
highNSAP). Consequently, these data suggest that removing
the strong competitive effect of the linear high affinity
enzymes may allow ecto-AK to raise ATP concentrations
within a nucleotide mixture dominated by ADP.
Based on this analysis of the high affinity group, we evaluated
the role of ecto-AK under steady-state conditions, in which
ASL exhibits an ADP/ATP concentration ratio of 20 (Table
3). The model predicts that a high affinity inhibitor mixture,
excluding the ecto-AK inhibitor (Ap5A), would raise the ASL
ATP concentration by 6-fold. The therapeutic potential of
this approach is illustrated by the fact that CCSmimicking nor-
mal breathing produced a similar increase in ASL ATP level
(Fig. 4C), which restoredmucus transport on the airway epithe-
lial surfaces of CF patients (10). The physiological importance
of ecto-AK for the regulation of steady-state nucleotide levels
was also demonstrated in human hepatocytes, where it reg-
ulates P2Y13 (ADP) receptor-mediated high density lipopro-
tein endocytosis (70). The ecto-AK inhibitor stimulated high
density lipoprotein endocytosis in the absence of exogenous
substrates, supporting a significant role in cholesterol trans-
port under steady-state conditions. Altogether, the model
and experimental data suggest that aerosolization of an
inhibitor mixture against the high affinity enzymes (exclud-
ing Ap5A) may stimulate airway clearance in CF patients.
The fact that blocking NSAP did not affect the steady-state
ATP level suggests that levamisole may be omitted. Further
refinement of the high affinity enzyme inhibitor mixture for
the treatment of obstructive lung diseases awaits the discov-
ery of specific noncompetitive inhibitors for NTPDase 1 and
the E-NPPs.
The regulation of ASL nucleotides through cell surface
metabolism leads to the accumulation of another important
signaling molecule for airway defenses, i.e. Ado. We previously
demonstrated that two ectoenzymes contribute to the produc-
tion ofAdo on airway epithelial surfaces, ecto-5-NT andNSAP
(13). Although their characterization was conducted using
AMPas initial substrate (13), this study documented the impact
of the entire biochemical network on ASL Ado production
using ATP as initial substrate. Based on model simulations and
biochemical assays, we identified a negative relationship
between ATP 1 M and the time required for Ado concentra-
tion to reach the EC50 of A2B receptors for CFTR activation
(0.03M) (16, 17).Model simulations, in which the kinetic con-
stants KATP(in) and KADP(in) were blocked, suggest that this relation-
ship is caused by feed-forward inhibition of ATP on ecto-5-
NT, but not on NSAP. These data are in agreement with the
reported inhibition of purified ecto-5-NT by ATP and ADP
(71, 72). Although the inhibitorymechanismhas not been iden-
tified, the insensitivity of NSAP may be partially because of its
capacity to eliminate ATP and ADP. Altogether, these results
emphasize the critical importance of studying the properties of
ectonucleotidases using experimental designs accounting for
the entire biochemical network, as the suppression of ecto-
5-NT activity by ATP would have been missed by protocols
isolating the AMP3 Ado reaction.
In human airways, feed-forward inhibition is not expected to
play a significant role in the regulation of purinergic signaling,
as epithelial surfaces are not normally exposed to 1 M ATP
(73–75). However, this regulatorymechanismmay become rel-
evant during injury-induced ATP release to prevent A2B recep-
tor desensitization (76) and/or excessive inflammatory
responses caused by chronically high Ado concentrations (77).
But even under these circumstances, NSAP activity would be
expected to compensate for the reduction in ecto-5-NT activ-
ity caused by excess ATP. Consequently, this regulatory mech-
anism may be more relevant for purinergic signaling in tissues
expressing ecto-5-NT, with little or no NSAP. For instance,
feed-forward inhibition is not detected on vascular smooth
muscle cells (78), which express NSAP (79). In contrast, endo-
thelial surfaces do not express NSAP (80) and exhibit an inhib-
itory effect of ADP on ecto-5-NT activity (59, 81). Because
ADP activates platelets andAdo suppresses their activation (31,
82), feed-forward inhibition was proposed to regulate throm-
bus formation during endothelial repair. A mathematical
model of extracellular nucleotide metabolism on endothelial
cells predicts an inhibition of Ado production by 1–10MADP
(57–59). Because activated platelets release 1 mM ADP on
endothelial surfaces (31), feed-forward inhibition would create
a time gap between ADP- and Ado-mediated responses, allow-
ing sufficient time to consolidate the thrombus while minimiz-
ing spread beyond the site of damage. Consequently, two fac-
tors determine the importance of feed-forward inhibition for
purinergic signaling, the ecto-5-NT/NSAP activity ratio and
local nucleotide concentrations.
In conclusion, this study provides a robust model for the
regulation of two essential signaling molecules for airway
defenses, ATP and Ado. The equations capture the complex
behavior of the linear and nonlinear reactions and the dynamic
Model of Airway Nucleotide Regulation
SEPTEMBER 26, 2008 • VOLUME 283 • NUMBER 39 JOURNAL OF BIOLOGICAL CHEMISTRY 26817
interplay between the ectoenzymes. Furthermore, the model
reproduces ASL nucleotide regulation under both static condi-
tions and mechanical stress mimicking normal breathing.
Finally, therapeutic applications are proposed based on an
interactive approach between simulations and biochemical
assays. We are currently developing a model for the regulation
of the ASL volume by P2Y2 and A2B receptor-mediated ion
channel activities. In the near future, the integration of these
twomodels should provide insightful information on the inter-
actions between the biochemical and functional networks of
purinergic signaling on airway epithelia under normal and
pathological conditions, as well as novel guidelines for the
development of efficient treatments of chronic obstructive lung
diseases.
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